Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip G Conaghan

Showing results (61-70 of 503) with videos related to

Pageof 51
Sort By:
Annals of the Rheumatic Diseases|September 1, 2010
Effect of intra-articular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritisGlenn Haugeberg, Sarah Morton, Paul Emery, et al.
Expert Opinion on Therapeutic Targets|October 25, 2024
Targeting the TRPV1 pain pathway in osteoarthritis of the kneeAli Mobasheri, François Rannou, Stefan Ivanavicius, et al.
The Journal of Rheumatology|April 17, 2004
A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the kneeRichard Day, Peter Brooks, Philip G Conaghan, et al.
BMC Musculoskeletal Disorders|February 2, 2022
Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritisPhilip G Conaghan, Lucy Abraham, Lars Viktrup, et al.
Evidence-Based Medicine|September 4, 2017
Quality of reporting of harms in randomised controlled trials of pharmacological interventions for rheumatoid arthritis: a systematic reviewMuhammad Abdul Hadi, Gretl A McHugh, Philip G Conaghan
Best Practice & Research. Clinical Rheumatology|December 25, 2015
Monitoring in established RA: Role of imaging and soluble biomarkersJoshua F Baker, York Kiat Tan, Philip G Conaghan
Current Pharmaceutical Design|March 12, 2015
Biological therapies in osteoarthritisClaire Y J Wenham, Michael McDermott, Philip G Conaghan
Osteoarthritis and Cartilage|March 4, 2026
Digital mobility measures in osteoarthritis: endpoint innovation without losing what mattersRobin Christensen, Philip Rask Lage-Hansen, Philip G Conaghan
Journal of Foot and Ankle Research|December 3, 2019
The prevalence and impact of self-reported foot and ankle pain in the over 55 age group: a secondary data analysis from a large community sampleAnne-Maree Keenan, Chris Drake, Philip G Conaghan, et al.
Health and Quality of Life Outcomes|July 17, 2007
A longitudinal evaluation of the Center for Epidemiologic Studies-Depression scale (CES-D) in a rheumatoid arthritis population using Rasch analysisTanya Covic, Julie F Pallant, Philip G Conaghan, et al.
Pageof 51

Showing results (61-70 of 503) with videos related to

Sort By:
Pageof 51
Annals of the Rheumatic Diseases|September 1, 2010
Effect of intra-articular corticosteroid injections and inflammation on periarticular and generalised bone loss in early rheumatoid arthritisGlenn Haugeberg, Sarah Morton, Paul Emery, et al.
Expert Opinion on Therapeutic Targets|October 25, 2024
Targeting the TRPV1 pain pathway in osteoarthritis of the kneeAli Mobasheri, François Rannou, Stefan Ivanavicius, et al.
The Journal of Rheumatology|April 17, 2004
A double blind, randomized, multicenter, parallel group study of the effectiveness and tolerance of intraarticular hyaluronan in osteoarthritis of the kneeRichard Day, Peter Brooks, Philip G Conaghan, et al.
BMC Musculoskeletal Disorders|February 2, 2022
Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritisPhilip G Conaghan, Lucy Abraham, Lars Viktrup, et al.
Evidence-Based Medicine|September 4, 2017
Quality of reporting of harms in randomised controlled trials of pharmacological interventions for rheumatoid arthritis: a systematic reviewMuhammad Abdul Hadi, Gretl A McHugh, Philip G Conaghan
Best Practice & Research. Clinical Rheumatology|December 25, 2015
Monitoring in established RA: Role of imaging and soluble biomarkersJoshua F Baker, York Kiat Tan, Philip G Conaghan
Current Pharmaceutical Design|March 12, 2015
Biological therapies in osteoarthritisClaire Y J Wenham, Michael McDermott, Philip G Conaghan
Osteoarthritis and Cartilage|March 4, 2026
Digital mobility measures in osteoarthritis: endpoint innovation without losing what mattersRobin Christensen, Philip Rask Lage-Hansen, Philip G Conaghan
Journal of Foot and Ankle Research|December 3, 2019
The prevalence and impact of self-reported foot and ankle pain in the over 55 age group: a secondary data analysis from a large community sampleAnne-Maree Keenan, Chris Drake, Philip G Conaghan, et al.
Health and Quality of Life Outcomes|July 17, 2007
A longitudinal evaluation of the Center for Epidemiologic Studies-Depression scale (CES-D) in a rheumatoid arthritis population using Rasch analysisTanya Covic, Julie F Pallant, Philip G Conaghan, et al.
Pageof 51